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PURPOSE. To examine the association between visual function response (VFR) and
inflammation reduction in active noninfectious uveitis of the posterior segment (NIU-PS).
METHODS. Phase 3 SAKURA Study 1 randomized 347 subjects in a double-masked fashion to
receive injections of intravitreal sirolimus 44 lg (n ¼ 117); 440 lg (n ¼ 114); or 880 lg (n ¼
116) every other month. Vitreous haze (VH) response, a measure of inflammation reduction,
was defined as a VH score of 0 or 0.5þ at month 5 based on the modified Standardized Uveitis
Nomenclature Scale. Visual function was assessed with best-corrected visual acuity (BCVA)
and the National Eye Institute (NEI) Visual Function Questionnaire-25 (VFQ-25). In this post-
hoc analysis, principal component analysis was used to reduce the information in the
multidimensional visual function outcome to a restricted number of independently relevant
VFR measures. Minimal clinically important differences (MCID) for the VFQ-25–derived
components were based on the standard error of measurements. Overall VFR was defined as
either a BCVA improvement of ‡2 lines, or an improvement exceeding the MCID in the VFQ-
25 based visual function measures.
RESULTS. The VFQ-25 composite score (VFQCS) and mental health subscale score (VFQMHS)
were retained as relevant VFRs, with MCIDs of 4.3 and 11.7 points, respectively. A vitreous
haze response was significantly associated with each VFR measure: VFQCS (odds ratio [OR] ¼
2.23; P ¼ 0.0004); VFQMHS (OR ¼ 2.84; P < 0.0001); BCVA (OR ¼ 2.60; P ¼ 0.0009), and
overall VFR (OR ¼ 2.65; P < 0.0001).
CONCLUSIONS. Inflammation reduction to a VH score of 0 or 0.5þ was significantly associated
with improved visual function. Achieving a VH response of 0 or 0.5þ is a patient-relevant
outcome.
Keywords: minimal clinically important difference, non-infectious uveitis, patient reported
outcomes, posterior segment, principal components analysis, VFQ-25, visual acuity, visual
function response
Uveitis is a potentially blinding inflammatory ocular condi-tion that predominantly affects young adults in their active
years of life.1–4 Chronic uveitis with long-standing ocular
inflammation can cause complications with secondary visual
impairment including cystoid macular edema, glaucoma and
cataract.1,5–9 In addition to vision loss, patients with non-
infectious uveitis (NIU) report markedly decreased vision- and
health-related quality of life (QoL).10–13 A comprehensive
assessment of visual functioning is therefore paramount in
studies of NIU, but the best method to quantify this outcome is
not well-defined.14,15 Although distance visual acuity (VA) is the
standard measure of visual function in most ophthalmologic
studies, it is an imperfect indicator of day-to-day visual
functioning, as it fails to capture the full impact of ophthalmic
disease on a patient’s life.16,17 Best-corrected VA (BCVA) does
not assess other patient-related factors such as general health,
mood, and compliance.18,19 Also, BCVA is considered a poor
marker of drug efficacy in inflammatory eye diseases as the
impact of uveitis on VA depends on both the disease activity as
well as the damage caused by the disease.19 Since NIU is a
heterogeneous collection of uveitic conditions characterized by
intraocular inflammation and presents with a wide range of
clinical manifestations, it is clear that no single measure can
comprehensively capture the impact of disease or treatment
benefit.17,20 To complement clinical parameters such as
vitreous haze (VH) and BCVA, patient reported outcome
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(PRO) measures are increasingly used to represent the impact
of NIU disease or benefit of treatment experienced by the
patient.13,16,21–23 As a consequence, several outcomes are now
collected to assess the full impact of new treatments. These
measures are often related to each other to some degree,
making interpretation challenging. However, robust explorato-
ry methods exist to organize and summarize multiple
interrelated variables to reveal new meaningful information.24
We present a new measure for assessing visual functioning
i.e., Visual Function Response (VFR), which combines BCVA
and PRO measures, and investigate the clinical relevance of this
combined endpoint. Using a post hoc analysis of data obtained
from the SAKURA Study 1,25 a phase III clinical trial in subjects
with NIU of the posterior segment (PS) of the eye, we first
define a restricted set of clinically meaningful VFR compo-
nents, and secondly describe the associations between
different definitions of ocular inflammation and the newly
constructed VFR measures.
METHODS
SAKURA Trial Participants
This study of visual function outcomes is based on the SAKURA
Trial, which has been presented elsewhere.25 The SAKURA
Study 1, a phase 3, randomized, multicenter, double-masked,
multinational trial (ClinicalTrials.gov number, NCT01358266)
was conducted to evaluate the safety and efficacy of intravitreal
(IVT) injections of three doses of sirolimus for the treatment of
chronic NIU-PS of the eye. Participants were randomized 1:1:1
to receive IVT sirolimus 440 lg, 880 lg, or an active control
dose of 44 lg every alternate month for 5 months. A total of
347 participants with active posterior, intermediate or
panuveitis, and decreased BCVA attributable to uveitis were
randomized at 103 centers in 15 countries. The SAKURA trial
was conducted in accordance with the tenets of the
Declaration of Helsinki and informed consent was obtained
for all randomized participants. The primary endpoint was
defined as having a VH score of 0 at month 5 using the
Standardized Uveitis Nomenclature (SUN) photographic scale.
Additional predetermined secondary endpoints assessed at
month 5 included a VH response of 0 or 0.5þ, VH response of 0
or 2 units, use of rescue therapy, and change from baseline in
BCVA or in the National Eye Institute Visual Function
Questionnaire-25 (NEI VFQ 25) composite score. Rescue
therapy was considered any treatment with a therapeutic
effect on NIU in the PS, other than IVT sirolimus.25
Measures of Visual Function
At enrollment in the SAKURA Study 1, the visual function (VF)
outcomes were measured using BCVA (based on the Early
Treatment of Diabetic Retinopathy Study (ETDRS) protocol),
and vision-related function using the NEI VFQ-25.26,27 The NEI
VFQ-25 is a survey used across a wide range of eye diseases to
assess how ocular conditions and their therapy affect a
patient’s day-to-day functioning and well-being.13,22,28–30 The
VFQ-25 consists of a base set of 25 vision-targeted questions
representing 11 vision-related constructs or subscales, plus an
additional single-item general health-rating question. An overall
VFQ-25 composite score (VFQCS) is calculated as the
unweighted average from the vision-targeted scores, excluding
the general health item.27 Scores for each subscale and the
composite score range from 0 (worst vision functioning) to
100 (best vision functioning or minimal subjective impair-
ment). The VFQ was self-administered in the participant’s
native language. Across all non-US sites, the VFQ version
including 25 items was used. Whereas US participants used the
expanded 39-item questionnaire, we only analyzed those
questions included in the VFQ-25.31
Statistical Analyses
Clinical and VFQ-25 Database. All analyses were per-
formed using the intent-to-treat principle (including all
randomized participants). Missing data were imputed using
the last observation carried forward (LOCF) method. The
composite and subscale VFQ-25 scores were computed as per
the VFQ-25 scoring algorithm of Mangione et al.27
Identifying VFR Measures Through Principal Compo-
nents. The VFQ-25 is a PRO measure comprising multiple
items that assess various facets of ophthalmologic disease.27 If
all items of a PRO instrument are well correlated and can be
summarized in a single composite score, the instrument is said
to be unidimensional, meaning it measures a single latent trait
or common underlying concept.24,32 A principal component
analysis (PCA) is an established approach to empirically test
the unidimensionality of a PRO and was applied to examine the
unidimensionality of the VFQ-25 in the SAKURA NIU popula-
tion. A PCA works by reducing the multidimensionality of a
large number of interrelated scores, while retaining as much as
possible the variation present in the dataset. The outcome of a
PCA is a new set of variables, the principal components (PCs),
that are linear combinations of the original responses,
constructed in such a way that the first PC captures as much
variation as possible of the complete set of responses, whereas
the second PC is independent of the first one and captures as
much as possible of the remaining variation and so forth.33 If
the first PC captures over 60% of the variability, the PRO
dataset is said to be unidimensional and well captured by the
first PC.34,35 If the first PC captures a smaller proportion of the
variability, more than one PC is required to represent the
dataset. In this analysis phase, the multidimensional visual
function outcome is reduced to a restricted number of relevant
VFR measures that capture as much of the variation as possible.
Defining a VFR. For each of the VFR measures identified
from the PCA, the minimal clinically important difference
(MCID) is determined. The MCID is the smallest change or
difference in an outcome measure that is perceived as
beneficial and that would lead to a change in the patient’s
medical management.36 For our analysis, a distribution-based
approach, the Standard Error of Measurement (SEM) of the
VFQ-25 baseline values, was used to establish the threshold for
a meaningful improvement from baseline to month 5 in the
VFQ-25 scores.37 The SEM-based MCID was estimated as the
standard deviation of the measure multiplied by the square
root of one minus the reliability of the measure. Cronbach’s a
(a measure of how closely the items are related in the specific
multi-item domain) was used as the measure of reliability.38,39
For measures of VFR with a well-established clinical criterion of
response (e.g., BCVA), the existing threshold of an improve-
ment of ‡2 lines of letters was used to distinguish response
from nonresponse.13,40 An overall VFR based on these three
individual measures was also generated. Participants who
required rescue therapy were systematically categorized as VF
nonresponders.
Measuring the Associations Between VFR and VH.
Associations between the different definitions of ocular
inflammation and the binary measures of VFR (responder
versus nonresponder) were estimated through logistic regres-
sion, incorporating the treatment factor (dose of sirolimus) as a
fixed effect. The definitions of VH used in this post hoc analysis
were consistent with the primary endpoint of the SAKURA
Trial (a VH score of 0 at month 5) and with the key secondary
VH endpoints (i.e., a VH score of 0 or 0.5þ at month 5; a VH
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score of 0 or a decrease of at least 2 units from baseline in VH
score at month 5). Analyses were carried out using statistical
software (SAS version 6.3; SAS Institute, Cary, NC, USA) and a
significance level of 0.05 was considered significant.
RESULTS
Clinical and VFQ-25 Database
The characteristics of SAKURA participants have been pub-
lished elsewhere.25 Briefly, the participants were predominant-
ly white (47.3%) and female (59.9%), with a mean age of 46.5
years (614.5). A majority (68%) of participants had interme-
diate or posterior uveitis while 66.6% had bilateral uveitis, and
77.8% had no systemic disease associated with their uveitis
diagnosis. The median (range) time from initial uveitis
diagnosis to enrollment was 26.2 (0.1–411.7) months. The
mean visual acuity in the study eye was 65.3 (615.9) ETDRS
letters (20/50 Snellen equivalent). The mean VFQCS score at
baseline was 65.8 (619.3) points, and mean subscale scores
ranged from 54.6 (vision-specific mental health) to 85.2 (color
vision; Fig. 1).
Identifying VFR Measures Through Principal
Components
The output of the PCA showed that the first PC (PC1) captured
a substantial but insufficient proportion (50.9%) of the
variation to consider the VFQ-25 dataset unidimensional.
Principal components 2 and 3 explained an additional 6.8%
and 5.6% of the variation, respectively (Supplementary Fig. S1).
The PC1 correlated highly with the VFQCS (q¼0.99), while its
correlation with BCVA was low (q¼ 0.34; Supplementary Fig.
S2). The items of VFQ-25 best describing the variation in PC2
and PC3, based on their loadings (i.e., the weight given to each
question in constructing the PC), were mainly those included
in the mental health subscale (Supplementary Figs. S3A, S3B).
Hence, the key VFR measures retained from the PCA were the
VFQCS, as a surrogate for PC1, the BCVA score providing
information that is complementary to PC1, and the VFQ-25
mental health subscale score (VFQMHS). The thresholds of
MCID for a clinically meaningful response were ‡4.3 units for
the VFQCS (Cronbach’s a ¼ 0.95) and ‡11.7 units for the
VFQMHS (Cronbach’s a¼0.77). The threshold of MCID for the
BCVA score was set at ‡2 VA lines (10 ETDRS letters). Patients
with a value above the MCID are considered responders.
Treatment Effect on Visual Function Response
Treatment with sirolimus 440 lg did not result in a significantly
higher proportion of responders as compared to the active
control for the BCVA score (21.1% vs. 18.8%, OR: 1.15, P ¼
0.67); the VFQCS (40.7% vs. 35.9%, OR: 1.23, P ¼ 0.45); the
VFQMHS (29.2% vs. 26.5%, OR: 1.14, P¼ 0.65); and the overall
VFR (51.3% vs. 43.6%, OR: 1.36, P¼ 0.24). Similarly, results for
sirolimus 880 lg vs. 44 lg were comparable. Treatment with
sirolimus 880 lg did not result in a significantly higher
proportion of responders as compared to the active control for
the BCVA score (20.7% vs. 18.8%, OR: 1.13, P ¼ 0.72); the
VFQCS (41.4% vs. 35.9%, OR: 1.26, P ¼ 0.39); the VFQMHS
(32.8% vs. 26.5%, OR: 1.35, P¼0.30) or the overall VFR (50.9%
vs. 43.6%, OR: 1.34, P ¼ 0.27).
Measuring the Associations Between VFR and VH
Achieving a VH score of 0 was not significantly associated with
the VFQCS response (OR ¼ 1.51, P ¼ 0.124), and VFQMHS
response (OR ¼ 1.72, P ¼ 0.051). However, achieving a VH
score of 0 was significantly associated with a BCVA ‡2 lines
improvement (OR¼2.28, P¼0.006) and the overall VFR (OR¼
1.77, P < 0.0001; Fig. 2A).
There was a statistically significant association between
reaching a VH score of 0 or 0.5þ and each of the VFR measures
(i.e., VFQCS response (OR ¼ 2.23, P ¼ 0.0004); VFQMHS
response (OR¼ 2.84, P < 0.0001); BCVA response (OR¼ 2.60,
P¼ 0.0009); and overall VFR response (OR¼ 2.65, P < 0.0001;
Fig. 2B).
Considering an endpoint of reaching a VH score of 0 or a 2-
unit decrease, a significant association was observed only with
respect to BCVA response (OR ¼ 1.40, P ¼ 0.0281; Fig. 2C).
FIGURE 1. BCVA, VFQ-25 composite score, and VFQ-25 subscales scores at baseline.
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The corresponding proportion of responders for the
individual VFR measures and the overall VFR are presented
according to the different VH response definitions in the
Table.
DISCUSSION
Vitreous haze is the current standard for assessing posterior
segment inflammation and is accepted as a valid surrogate
endpoint for disease activity.15,17,19,41–43 Endpoints such as
improvement in BCVA are also considered for assessing
efficacy in clinical trials of uveitis as it reflects a clinical
endpoint of significance to the patient.41 Although there is
limited evidence on the significance of VH as a clinical marker
for assessing therapeutic benefit in NIU-PS, the analysis results
of SAKURA Study 1 data reported here demonstrates the
patient relevance of ocular inflammation control measured
through the intermediate endpoint of VH.43–45 Achieving a
VH score of 0 or 0.5þ at month 5 following treatment was
significantly associated with clinically meaningful improve-
ments in patient visual functioning. Also, we observed a
significant association between inflammation control and
meaningful improvement in BCVA, regardless of the definition
used for VH control. To the best of our knowledge, this is the
first study to report the association between VFR and VH
response for NIU-PS.
Principal component analysis is a data-driven procedure
frequently used in exploratory data analysis, including PRO
research. In ophthalmology, it is a recognized method to
validate new questionnaires, or to endorse established
questionnaires applied to new conditions.24,34,46 The VFQ-25
generates a multidimensional dataset and like many PRO
instruments with multiple domains, its multiple scores are
combined to calculate a general score creating a composite
endpoint, the VFQCS.47 Composite endpoints have advantages
such as reducing multiplicity problems; however, the use of an
aggregate PRO score has limitations and its validity has been
critiqued as it may not capture all clinically important variation
in the set of multiple items of the instrument.16,47 If all items of
a PRO instrument are well related and can be summarized in an
aggregate score, the instrument is said to be unidimensional.
Typically, it is expected that the first PC captures a minimum of
60% of the variation to label an instrument as unidimension-
al.34,35 Our PCA showed that the first PC captured 50.9% of the
relevant information suggesting that the VFQ-25 responses
from the SAKURA Study 1 population cannot be considered as
unidimensional. Hence, it is preferable to represent the VFQ-25
dataset through more than one single measure. Further
exploration of the PCA suggested VFQMHS as an additional
dimension of visual functioning. Our observations regarding
multidimensionality are in line with those made by other
researchers. Marella et al.35 studied the psychometric validity
of the VFQ-25 in a low vision population and concluded that
the VFQ-25 is a better-performing instrument when split into a
visual functioning and socioemotional scale. Similarly, other
researchers34 found multidimensionality with near vision items
loading onto the second PC. Nevertheless, the VFQCS
demonstrated good internal consistency, a Cronbach’s a of
0.95, consistent with psychometric evaluation results in other
NIU studies.29
The thresholds of MCID for the VFQCS and VFQMHS were
estimated using a distribution-based approach. In the absence
of a strong correlation between BCVA and the VFQCS (q ¼
0.34), the use of a distribution-based over an anchor-based
approach is justified. While the MCID assessed using SEM by
Naik et al.29 found a 3.86-point change in VFQCS and 8.92-
point change in VFQMHS to be clinically meaningful, the
FIGURE 2. (A–C) Associations between VH score and VFR measures at
month 5. Odds ratio shows the odds of being a VFR responder when
being a VH responder estimated from logistic regression model with
treatment factor as a fixed effect. 95% CI, Upper and lower 95%
confidence interval.
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SAKURA Study 1 data identified a threshold of 4.3 and 11.7
units for VFQCS and VFQMHS similar to other studies.48,49
Previous research demonstrated that the NEI VFQ-25 is a
reliable, valid and responsive instrument to assess vision-
related functioning in NIU-PS.29 Our research did not aim to
test the psychometric performance of the VFQ-25 in the
SAKURA Study 1 population. Rather, we investigated the
association between different definitions of VH response and
patient-reported outcomes. Our VFQ-25 findings showed
significant associations between control of ocular inflamma-
tion, when defined as VH score of 0 or 0.5þ, and meaningful
improvements in the VFQCS or VFQMHS scores. This suggests
that from a patient perspective, the standard threshold for the
NEI photographic VH scoring equal to 0 may be too strict.
Clinical trials in NIU typically use the NEI technique to grade
the severity of VH whereby the clinical examination of the
posterior pole is compared against a standard set of
photographs. This photographic assessment technique comes
with limitations (subjective, poorly discriminatory at lower
levels of VH, limited sensitivity in trial context), which may
contribute to nonsignificant correlation between markers of
disease activity (VH) and measures of visual function
(VF).42,45,50 Nevertheless, our BCVA findings show that
regardless of the VH threshold used, patients confer a visual
function benefit.
Noninfectious uveitis is a heterogeneous disease character-
ized by intraocular inflammation that manifests as a collection
of distinct symptoms and differs from other ocular conditions
affecting VA. Patients with NIU experience symptoms that are
not well detected by VA testing. Therefore, to capture patient
benefit of inflammation control, additional dimensions are
needed. The overall VFR used here combines three single
endpoints in one outcome to demonstrate the overall effect of
the disease. Patients who experience any of the events
specified by the components are considered to have experi-
enced the composite endpoint.51,52 A composite endpoint can
combine patient-, observer- or clinician-reported measures.47,53
Composite endpoints have been progressively included in
cardiology, HIV and rheumatology clinical trials.54–56 Advan-
tages are increased statistical efficiency because of higher
event rates, avoidance of an arbitrary choice between several
outcomes of the same disease process, and a means of
assessing the effectiveness of a PRO that addresses more than
one aspect of the patient’s health status.52,54,57–59 In ophthal-
mology, the frequent use of a composite outcome measure may
be driven by the lack of a single outcome measure suitable for
the wide range of clinical entities in the studied population.17
Common measures of disease activity have classically been VH
and macular edema, while high-contrast distance BCVA has
been used in all clinical trials that included measures of visual
function performance. A combined endpoint based on BCVA
and PRO measures has not yet been reported in NIU-PS, even
though the burden of NIU is known to comprise reductions in
vision-related functioning in addition to vision loss. Exploring
new measures of visual functioning for inflammatory eye
diseases is supported in the literature.10,12,13,17,19,22 As
reported in this study, the value of PRO measures of vision-
related functioning consists of complementing clinical mea-
sures such as VH and VA, and providing the patient’s
perspective on disease burden and outcomes of treatment,
hence capturing a more complete response to disease
control.60
While NIU may present many potential insults to visual
functioning, it is notable that mental health appears the most
impaired vision-related domain (lowest subscale score) across
several NIU populations including the SAKURA Study
1.13,22,61 Although results for all VFQ-25 items differ
significantly from the normal-vision population, it is likely
that not all items are equally relevant to uveitis or that NIU-PS
patients may have specific items impacting their QoL more
than others.12,17 A significant decline of psychological well-
being, despite an unequivocal physical health status similar to
the normal-vision population, is often reported by patients
with uveitis.12 This is not surprising given that activities of
daily life are impacted with vision impairment, which in turn
affects the psychological status of the patient. Qian et al.61
reported depression to be a prevalent comorbidity in patients
with ocular inflammatory disease, with VFQ-25 scores
(composite and subscales) in the same range as those found
in other studied uveitis populations. Our results in the
SAKURA Study 1 found a low correlation between BCVA and
the VFQCS (q ¼ 0.34), indicating that VA and PRO measure
different and complementary aspects of visual functioning.
The apparent absence of correlation between BCVA and VFQ-
25 responses may be due to unmeasured symptoms such as
depression, known to affect visual functioning. Depression
may impact a patient’s visual experience without a propor-
tionate change in VA and hence a combined VFR endpoint
TABLE. Visual Function Responders for Each VFR Measure According to the Different Definitions of VH Response
VFR Measure
VH 0* VH 0.5þ* VH 0 or 2-Unit Change*
VH ¼ 0,
N ¼ 72
VH >0,
N ¼ 275†
VH 0.5þ,
N ¼ 180
VH >0.5þ,
N ¼ 167†
VH 0 or ‡2-Unit
Decrease, N ¼ 97
VH >0 or <2-Unit
Decrease, N ¼ 250†
n (%) n (%) n (%) n (%) n (%) n (%)
VFQCS‡ 34 (47.2) 102 (37.2) 87 (48.3) 49 (29.5) 42 (43.3) 94 (37.8)
BCVA ‡2 lines‡ 23 (31.9) 47 (17.1) 48 (27.2) 21 (12.5) 27 (27.8) 43 (17.2)
VFQMHS‡ 28 (38.9) 74 (27.0) 71 (39.4) 31 (18.7) 32 (33.0) 70 (28.1)
Overall VFR‡ 43 (59.7) 125 (45.6) 108 (60.0) 60 (36.1) 53 (54.6) 115 (46.2)
* Vitreous haze response definitions follow the primary and secondary endpoints of VH response in the SAKURA Study 1: the primary VH
endpoint defined as having a VH score of 0 at month 5; the secondary VH endpoint defined as having a VH score of 0 or 0.5þ at month 5; the
additional secondary VH endpoint defined as having a score of VH 0 or a ‡2-unit change. For each VH response definition, N represents the number
of participants achieving a VH response (versus nonresponse); n represents the number of participants with a visual function response (%) for the
respective VFR measure.
† For the VFQCS, VFQMHS and overall VFR, the denominator was 274, 166, and 249 in the VH 0, VH 0.5þ, and VH 0 or 2-unit change groups,
respectively, due to one patient for which no VFQ-25 assessment was available at month 5.
‡ AVFQCS responder is a participant with a VFQCS change from baseline to month 5 of ‡4.3 points. A BCVA ‡2-lines responder is a participant
with a BCVA change from baseline to month 5 of ‡2 lines of VA. A VFQMHS responder is a participant with a VFQMHS change from baseline to
month 5 of ‡11.7 points. An overall VFR responder is a participant with a response based on the VFQCS or the BCVA score or the VFQMHS change
from baseline to month 5.
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may be more sensitive to detect dysfunctional vision
compared to VA testing alone.
Several limitations should be considered when interpret-
ing the findings from this study. First, given the inclusion and
exclusion criteria of the SAKURA study 1, the BCVA and
vision-related functioning may not be generalizable to all
patients with NIU-PS. Additional analyses (data not shown)
indeed demonstrated that achieving an overall VFR was
significantly associated with lower baseline values for the
BCVA, VFQCS, or VFQMHS compared with non-responders.
However, for the association analyses we considered an
endpoint of overall VFR that allowed participants to be
classified as a responder if they experienced a meaningful
improvement in any of the 3 individual VFR measures. Thus, a
participant with a relatively high baseline BCVA score could
still be a VF responder based on improvement shown in other
dimensions of visual functioning (e.g., VFQMHS). Second, our
threshold for meaningful VFR for the VFQ-25 outcomes was
based on a distribution-based criterion (SEM) only, in absence
of patient or physician criteria. Nevertheless, the MCIDs
observed in the SAKURA Study 1 were in the range of those
observed in other NIU populations. Finally, the SAKURA Study
1 was a multicountry study including mainly Caucasian and
Asian populations. As the functional impact of treatment was
based on patient self-reporting and regional/cultural differ-
ences in reporting may exist, this can be considered a
limitation of the study. Nonetheless, the analysis of composite
data has the advantage that it avoids an arbitrary choice
between several important outcomes associated with a
patient’s disease status (visual acuity, daily functioning,
mental health, etc.) independent of regional or geographic
differences. Further research to investigate the role of
regional/cultural differences in predicting visual function
response may be warranted.
In conclusion, our results showed that improvement in
intraocular inflammation is significantly associated with
improvement in visual functioning defined by BCVA, the
VFQCS or the VFQMHS. The VFQ-25 complements clinical
measures of disease activity (i.e., VH) and provides a patient
perspective on burden of disease. A clinically measurable VH
response of 0 or 0.5þ indicates an improvement in visual
functioning as perceived by the patient. New measures for VFR
may be more sensitive and meaningful outcomes to the patient
than the classical VA and vision-related functioning measures.
In addition, health care practitioners, payer decision-makers,
and health technology assessment authorities may perceive
this combined endpoint as more patient relevant than
endpoints of disease activity.
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